Adult Dosing
Production of secretory endometrium
- 250 mg IM x1/wk
- Start therapy between 16 wks, 0 days and 20 weeks, 6 days of gestation
- Continue administration x1/wk until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first
Pediatric Dosing
Production of secretory endometrium
- >16 yrs, same as adult dosage
Note: Safety and effectiveness in pediatric patients <16 yrs of age have not been established
[Outline]
See Supplemental Patient Information
- Discontinue therapy on occurrence of arterial or deep venous thrombotic or thromboembolic event
- Allergic reactions, including urticaria, pruritus and angioedema, have occurred with use of this drug or with other products containing castor oil; discontinue therapy the drug on development of such reactions
- Decrease in glucose tolerance has occurred in some patients on using this drug. Carefully monitor pre-diabetic and diabetic women
- Some degree of fluid retention has occurred. Carefully monitor women with conditions that might influence this effect
- Monitor women having a history of clinical depression. Discontinue therapy on recurrence of clinical depression
- Carefully monitor women who develop jaundice/hypertension while receiving therapy with this drug and consider whether the potential benefit of use warrants continuation
Cautions: Use cautiously in:
- Renal dysfunction
- Diabetic patients
- Cardiac disorder
- Edema
- Hypertension
- Depression
- Jaundice
- Preeclampsia
- Epilepsy
- Migraine
- Asthma
Supplemental Patient Information
- Advise patients to contact their physician on noticing increased discomfort over time, oozing of blood or fluid, or inflammatory reactions at the injection site
Pregnancy Category:B
Breastfeeding: Detectable amounts of progestins are excreted in the milk of mothers receiving progestin treatment. Manufacturer advises to discontinue this drug at 37 weeks of gestation or upon delivery.
